VCP and cancer: Although clinical trials of CB-5083 for solid tumors and hematological malignancies were recently prematurely terminated due to the off-target effect on PDE6 resulting in ocular dysfunction, additional VCP inhibitors are being explored as clinical leads for cancer treatment.